Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
3(23%)
Results Posted
0%(0 trials)

Phase Distribution

Ph early_phase_1
1
8%
Ph phase_1
1
8%
Ph phase_4
2
15%
Ph not_applicable
7
54%
Ph phase_2
1
8%

Phase Distribution

2

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution12 total trials
Early Phase 1First-in-human
1(8.3%)
Phase 1Safety & dosage
1(8.3%)
Phase 2Efficacy & side effects
1(8.3%)
Phase 4Post-market surveillance
2(16.7%)
N/ANon-phased studies
7(58.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

3

trials recruiting

Total Trials

13

all time

Status Distribution
Active(3)
Completed(5)
Terminated(2)
Other(3)

Detailed Status

Completed5
unknown3
Recruiting3
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
13
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (8.3%)
Phase 11 (8.3%)
Phase 21 (8.3%)
Phase 42 (16.7%)
N/A7 (58.3%)

Trials by Status

unknown323%
recruiting323%
withdrawn215%
completed538%

Recent Activity

Clinical Trials (13)

Drug Details

Intervention Type
PROCEDURE
Total Trials
13